AGP Picks
View all

IRSF backs male participation in Unravel Rett trial

4 hours ago
IRSF backs male participation in Unravel Rett trial
By AI, Created 15:15 UTC, Nov 17, 2026, AGP -

The International Rett Syndrome Foundation funded a protocol amendment that could open Unravel Biosciences’ Phase 1 Rett syndrome trial in Colombia to males. If approved by Colombia’s regulator in January 2027, it would be only the second Rett clinical trial worldwide to enroll males.

Why it matters: - The amendment could expand Rett syndrome research to males, a group historically left out of clinical trials. - The change could help researchers test whether existing trial endpoints capture treatment response in males as well as females. - The effort could generate data that improves future trial design and broadens access to investigational therapies.

What happened: - The International Rett Syndrome Foundation funded a protocol amendment for Unravel Biosciences’ REVOLUTION Phase 1 clinical trial in Colombia. - The amendment would allow males to participate in the ongoing study of an investigational oral treatment for Rett syndrome. - The funding is the first project supported through IRSF’s Males with Rett Fund, called the MR. Fund. - The amended protocol has already received approval from the Clinical Research Ethics Committee of Antioquia, or CEICA. - Colombia’s national health regulator, INVIMA, is expected to review the amendment in January 2027.

The details: - REVOLUTION is registered as NCT07150013. - The study is evaluating RVL-001, an investigational oral formulation of vorinostat identified through Unravel Biosciences’ drug discovery platform. - Preclinical research published in July 2025 showed improvements in neurological, gastrointestinal and other symptoms in Rett syndrome animal models. - The Phase 1 study began dosing participants in May 2026 at the PECET clinical research center in Medellín, Colombia. - The trial is placebo-controlled and originally planned to enroll 15 participants ages 6 to 21. - The amended protocol would expand the age range to 3 to 25. - The amendment would allow males to enroll within the existing participant target. - Researchers would also be able to assess whether the endpoints used for females measure treatment response accurately in males. - The study includes RNA sequencing to track gene expression trajectory in each participant. - That molecular data could help researchers understand individual treatment responses and identify who may be most likely to benefit from specific therapies.

Between the lines: - IRSF is using targeted funding to push a long-running shift in Rett research from a female-only assumption to a broader view of the disease. - The protocol change matters beyond this one study because trial design often shapes who gets counted in later research and eventual treatment development. - The RNA sequencing component suggests the trial is aiming to pair clinical outcomes with molecular signals, not just symptom scoring.

What's next: - INVIMA’s decision in January 2027 will determine whether males can be enrolled in REVOLUTION. - If approved, REVOLUTION would become only the second Rett syndrome clinical trial worldwide open to males. - IRSF said the MR. Fund will continue supporting research that explicitly includes males with Rett syndrome. - Unravel Biosciences said the expanded study could inform the continued development of RVL-001 and future Rett research.

The bottom line: - IRSF’s first MR. Fund investment could make male inclusion in Rett syndrome trials a practical standard, not an exception.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Bogotá Daily Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Bogotá Daily Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.